Peregrine Pharmaceuticals Upgraded by Roth Capital
Post# of 98055
Peregrine Pharmaceuticals Upgraded by Roth Capital (PPHM)
Roth Capital upgraded shares of Peregrine Pharmaceuticals (NASDAQ: PPHM) from a neutral rating to a buy rating in a research report released on Monday morning. Roth Capital currently has $2.70 price target on the stock 
.
Separately, analysts at Zacks upgraded shares of Peregrine Pharmaceuticals from a neutral rating to an outperform rating in a research note to investors on Thursday, December 27th. They now have a $1.50 price target on the stock.
Shares of Peregrine Pharmaceuticals traded down 6.87% during mid-day trading on Monday, hitting $2.17. Peregrine Pharmaceuticals has a one year low of $0.39 and a one year high of $5.50. The stock’s 50-day moving average is currently $1.. The company’s market cap is $287.6 million.
(0)
(0)NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
